Beijing Tongrentang (SHA:600085), through subsidiary Beijing Tongrentang Chinese Medicine, plans to renew a trademark license agreement with China Beijing Tongrentang (Group), according to a Shanghai bourse filing on Saturday.
The Chinese drugmaker's shares rose less than 1% at the close of Monday's trade.
The deal, which was first signed in 2013, would have been terminated on Dec. 31, but the parties agreed to renew it for two more years.
The pharmaceutical company proposed to enter into a supplemental agreement to review fee-exemption clauses in the deal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments